Latest News

Education Webinar Series – 5th Annual Fireside Chat

December 12, 2024

Featuring Dr. Karel Pacak, world-renowned pheochromocytoma and paraganglioma expert and Chair of the Medical Advisory Board, and Dr. Shonna Snyder, PPA Board Member & Patient. See questions asked and timing below.

The information presented on this webinar is for educational purposes only and should not substitute the advice of your doctor(s) and medical team because they have in depth knowledge of your medical history and current situation.

Questions
#1 at 13:30 – Can you give a brief research update with some of the most noteworthy developments since the last Fireside Chat?
#2 at 19:45 – How does immunotherapy distinguish between the healthy tissue in non-hereditary metastatic pheo?
#3 at 25:40 – How do you think AI will impact patient care and research in the future and how?
#4 at 29:45 – What are your thoughts on cyberknife and proton beam radiation for vagal paraganglioma and head and neck paraganglioma, in general?
#5 at 36:30 – How does the DICER-1 gene affect pheochromocytoma?
#6 at 37:35 – Can you please comment on iodine seed implantation as a treatment for metastatic disease?
#7 at 40:00 – Are there any updates on alpha PRRT and when will Belzutifan be available?
#8 at 44:35 – What is the likelihood of a recurrence of a paraganglioma recurring or coming back after surgery?
#9 at 50:15 – How often should I be monitored after diagnosis or surgery?
#10 at 54:39 – How likely is it for an older female SDHD patient develop new tumors or have tumors grow?
#11 at 58:25 – Are there any options for open retroperitoneal surgery for abdominal paraganglioma?
#12 at 1:01:30 – Can you please discuss safety considerations when undergoing embolization for a carotid body paraganglioma?
#13 at 1:04:16 – Do certain mutations have greater likelihood of being biochemically silent?
#14 at 1:08:05 – How is tumor size related to the strength of the catecholamine signal in the blood?
#15 at 1:09:42 – What are the effects of long-term exposure of catecholamines on the cardiovascular system and will that resolve after the tumor is removed?